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Abstract
Lehoux et al provide a highly valid contribution in conceptualizing value in value propositions for new health 
technologies and developing an analytic framework that illustrates the interplay between health innovation 
supply-side logic (the logic of emergence) and demand-side logic (embedding in the healthcare system). This 
commentary brings forth several considerations on this article. First, a detailed stakeholder analysis provides 
the necessary premonition of potential hurdles in the development, implementation and dissemination of a 
new technology. This can be achieved by categorizing potential stakeholder groups on the basis of the potential 
impact of future technology.  Secondly, the conceptualization of value in value propositions of new technologies 
should not only embrace business/economic and clinical values but also ethical, professional and cultural values, 
as well as factoring in the notion of usability and acceptance of new technology. As a final note, the commentary 
emphasises the point that technology should facilitate delivery of care without negatively affecting doctor-
patient communications, physical examination skills, and development of clinical knowledge. 
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Introduction
Lehoux et al provide a highly valid contribution in 
conceptualizing value in value propositions for new health 
technologies and developing an analytic framework that 
illustrates the interplay between health innovation supply-
side logic (the logic of emergence) and demand-side logic 
(embedding in the healthcare system).1 The authors emphasize 
the importance of meaningful contributions by three key 
stakeholders, namely entrepreneurs, investors and regulatory 
agencies in the early stages of the innovation lifecycles claiming 
that this will more likely result in successful uptake by users 
and an acceptably good return on investment for investors. 
The authors also highlight, through the literature, qualitative 
research and discussion, the multifactorial complexities and 
challenges involved in balancing the innovation policy, namely 
the supply side logics as determined by financial markets and 
business media, and the health policy demand-side logics 
that include health technology assessment, reimbursement 
and procurement. The authors however acknowledge, “New 
technologies constitute an important cost-driver in healthcare, 
but the dynamics that lead to their emergence remains poorly 
understood…” (p. 1). 
In this commentary, we would like to put forward several 
points, as part of the commentary of this article. 
Stakeholder Analysis
Lehoux et al decided to focus on three key stakeholders in 
their study. Although entrepreneurs involve clinical teams 
to provide valuable information regarding patient needs and 
health benefits of new technologies, capital investors look out 
for business opportunities of innovations to curb down health 
risks of extant technologies or clinical practice, and regulatory 
agencies aim towards achieving patient safety, and the efficacy 
and quality of technology, the minimally consulted users/
patients/clients often have to take what is on offer without a 
choice for alternatives. In addition, the client system revolving 
around the patient, in particular the informal caregiver is 
often overlooked. In the delivery of healthcare services and 
technologies, the patient should be the focus of attention. Van 
Hoof et al,2 Holtkamp et al,3 and van Hoof & Verkerk4 have 
come up with various frameworks for the incorporation of 
technology philosophy in order to help identify and map the 
needs of patients (and other stakeholders) within different 
user contexts. Such frameworks, however, do not deny the 
complexity of the intertwined world of stakeholder needs. In 
particular, for technologies that are still to be made available, 
defining all the potential stakeholders is challenging. 
Moreover, in terms of user acceptance, consulting potential 
end-users during the pre-implementation phase of new 
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technologies can lead to skewed representations towards the 
usefulness of such devices that would have been more mature 
and crystallised if people had the chance to experience and 
engage with the devices in question.5 Therefore, it is important 
to envisage the potential impact of future technology, and this 
entails primarily categorizing potential stakeholder groups 
that could be affected, as well as recognising the differences 
between pre- and post-implementation research.6 
A suggested approach is using temporal stakeholder and 
event analysis, which transfers learning from different 
stakeholder groups’ experiences with previous technologies, 
to new technologies or systems. This analysis provides a 
structure that captures the lifecycle of technologies and 
outlines the impact on different stakeholder groups at each 
stage of the lifecycle.6 A robust stakeholder analysis provides 
the necessary premonition of potential hurdles in the 
development, implementation and dissemination of a new 
technology. A comprehensive analysis will more likely guide 
the course of development of technology early on, while 
considering affected stakeholders and the wider community.7 
On the other hand, the identification of too many stakeholders 
may be problematic in that these have specific interests that 
may separately or collectively impede the implementation 
of new technology, regardless of the clients’ intentions.2,8 On 
many occasions, the client’s consent is taken for granted. 
The example of the home telehealth solution reveals that the 
chronically ill and older adults, potentially identified at the 
end of the process, are accidental stakeholders.8
Defining “Value” in Value Propositions of New Technologies
The manner in which the three key stakeholders mentioned 
in the study define value is a clear reflection of the often-
limited business/economic focus adopted. The examples 
of innovations in the article alert us of this limitation and 
invite us to consider a broader and more comprehensive 
conceptualization of value in value propositions of new 
technologies. Additionally, the qualitative study highlights 
the vested interests of the three stakeholders, and therefore 
the fragmented manner in which value is conceptualized. For 
example, the authors lament, “Investors support technologies 
that generate health gains by accident, not by design.”1 The 
article also refers to investors, who because of their desire 
for a quick return on investment, and their aim to bring the 
venture to the most profitable exit, will only provide support 
for a limited period of time despite evidence of patient benefits 
and value creation for health systems. 
Entrepreneurs, who tap on their healthcare experience, seem 
to have a more balanced consideration of not only having the 
proposed technology generating revenues but also a capacity 
to generate health benefits and therefore do have a patient 
focus. The regulatory agencies also have a somewhat specific 
remit, namely that of focusing on safety and efficacy of new 
technologies relying on science, expertise and judgment 
when executing appraisals. While the values defined are of 
critical consideration, we propose stakeholders to collectively 
consider ethical concepts apart from the business/economic 
and clinical values that are described in more detail below. 
The first that comes to mind are the ethical values and 
aspects when proposing and considering new technologies.9 
Technology is considered to influence various human 
experiences, amongst them health.10 Although it influences 
social changes, and could be a source of power, vulnerability, 
and inequality, new technologies are still too often introduced 
with little critical reflection on their impacts.10 This is of 
particular concern in healthcare when the problematic 
allocation of scarce resources should leave little room for 
experimentation in view of the ever-rising healthcare costs 
and health inequalities. 
The second concept is the consideration of professional values 
of healthcare professionals, whose main goal is their ability to 
satisfy the needs of their patients and clients.11 In particular, 
professionals delivering chronic care value inter-collegial 
respect. Additionally, clinicians do not relate technological 
solutions for clinical problems. Therefore, for success in the 
implementation of new technologies, it is essential that these 
values are not disrupted and that clinicians should receive 
solid support and education to effectively link technological 
solutions to care recipients’ needs.11 
The third concept is the consideration of the social and 
cultural values of the value proposition. The extent to which a 
technology is effective in the world does not only depend on its 
technical aspects but also on how successful it is to match the 
social and ecological contexts where it is implemented.12 See, 
for instance, Moors and Peine,13 who discussed how to value 
health innovations within a broader socio-cultural context. 
Therefore, stakeholders should also consider the social and 
cultural aspects of technology in its design, implementation 
and dissemination.12 
The fourth concept is the consideration of usability, ie, 
user-oriented approach, which is considered an important 
determinant of acceptance.8 If a new technology satisfies three 
properties, namely effectiveness, efficiency and satisfaction, 
then it is more likely to be high on usability. Additionally, 
memorability and learnability are also considered important.8 
New technologies, if introduced successfully, will always to 
some extent disrupt existing ethical, professional or cultural 
practices. This encompasses more than just meeting user 
needs or professional values. There will always be socio-
material practices that arise during the implementation, which 
are the “locale” in which old values are contested and new 
values arise. These emerging and evolving values are critical 
in assessing a technology and determining its “success.” The 
distinction between a prosthetic logic (in which technologies 
are assessed according to how well they support the model of 
existing values) and a habilitating logic (in which technologies 
are assessed according to how far they allow new values to 
emerge reflexively) might help in this regard.13
A Note on Health Technology Assessment
The focus of technological assessments tends to be mostly on 
the positive and negative impacts or effects of a technology 
without much consideration of the manner with which they 
restructure our physical and social worlds.14 Winner argues, 
“The capacity and willingness to reflect on the significance 
of technology and to critically evaluate new technologies 
lags far behind our capacity for creating and disseminating 
technologies” (p. 48).14 Unless a more robust assessment is 
used that encompasses the biopsychosocial model of care, 
new technologies pose numerous challenges in the various 
stages from the development to adoption and subsequent 
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sustainability of the uptake.
Conclusion
In this commentary, we have highlighted only some aspects 
of how new health technologies can provide greater value 
to end-users and to society as a whole. The subject area is 
complex, challenging and continues to confound leaders of 
health systems. Our commentary is intended to shed more 
light on what Lehoux et al masterfully provided in their study. 
As a final note, we believe that technology should facilitate the 
delivery of care without negatively affecting doctor-patient 
communications, physical examination skills, the perception 
of safety and security among patients, and the development of 
clinical knowledge.15 A potential side effect of the increased 
usage of technology in healthcare is the rise in costs that may 
hamper the overall accessibility of cure and care services, 
both from a patient and a professional perspective. Indeed, 
since clinicians are becoming more dependent on technology, 
in particular for accessing patient information, reaching 
diagnoses and delivering care, undergraduate and professional 
development training on using medical technology in the 
domains of cure and care has become a must to ensure 
autonomy while interfacing with medical technology.15
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